EQS-News

Medios achieves double-digit growth in 2023 – Positive outlook for 2024 - Seite 2

Growth in both operating segments

The Pharmaceutical Supply segment generated external revenue of €1,558 million in the 2023 financial year (previous year: €1,390 million), which corresponds to an increase of 12.1% compared to the previous year. EBITDA pre¹ increased by 22.8% to €46.7 million (previous year: € 38.0 million).

The Patient-Specific Therapies segment generated external revenue of €226.0 million in the same period (previous year: €220.0 million), up 2.7% on the previous year. EBITDA pre¹ decreased by around 8.0% year on year to around €21.8 million (previous year: €23.7 million), which is mainly due to a decline in gross profit as a result of regulatory price reductions (auxiliary tax reductions) for some active ingredients since September 2022.

Positive outlook for the 2024 and 2025 financial years

The company expects revenue of €1.9 billion to €2.1 billion and EBITDA pre¹ of €82 million to €91 million for 2024. This expectation is based in particular on the assumption that Ceban will be fully consolidated from May 1, 2024.

Through the realization of synergies and further organic growth Medios expects revenue to increase to around €2.15 billion and EBITDA pre¹ to around €110 million in the 2025 financial year, which corresponds to a significant increase in the EBITDA pre¹ margin to 5.1%.

Key figures (IFRS)
in € million		2023		2022		∆ in %
Revenue		1,784.7		1,610.8		10.8
Pharmaceutical Supply		1,558.1		1,390.3		12.1
Patient-Specific Therapies		226.0		220.0		2.7
Services		0.6		0.5		14.1
EBITDA pre1		60.5		54.9		10.3
Pharmaceutical Supply		46.7		38.0		22.8
Patient-Specific Therapies		21.8		23.7		-7.8
Services		-8.0		-6.8		17.4
Cashflow from operating activities		16.4		37.1		-55.8

Medios AG's Annual Report 2023 is available for download on the Investor Relations website.